{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:07:34Z","timestamp":1784581654034,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hoc.2026.05.011","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:16:35Z","timestamp":1781126195000},"page":"557-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver Transplantation for Liver and Perihilar Neoplasms"],"prefix":"10.1016","volume":"40","author":[{"given":"Megan A.","family":"Satyadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2026.05.011_bib1","first-page":"172","article-title":"Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a nationwide analysis of two decades","volume":"12","author":"Abboud","year":"2024","journal-title":"J Clin Transl Hepatol"},{"issue":"44","key":"10.1016\/j.hoc.2026.05.011_bib2","doi-asserted-by":"crossref","first-page":"16630","DOI":"10.3748\/wjg.v20.i44.16630","article-title":"Advances in non-surgical management of primary liver cancer","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.011_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/curroncol32020082","article-title":"Advancements in locoregional therapies for unresectable intrahepatic cholangiocarcinoma","volume":"32","author":"O\u2019Donnell","year":"2025","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-One-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","article-title":"Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-Year review of 574 consecutive resections","volume":"258","author":"Nagino","year":"2013","journal-title":"Ann Surg"},{"issue":"2S1","key":"10.1016\/j.hoc.2026.05.011_bib7","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","article-title":"OPTN\/SRTR 2023 annual data report: liver","volume":"25","author":"Kwong","year":"2025","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.011_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"10.1016\/j.hoc.2026.05.011_bib9","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.011_bib10","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.011_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/jlts.2002.34892","article-title":"Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the milan criteria and the Pittsburgh modified TNM criteria","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transplant"},{"key":"10.1016\/j.hoc.2026.05.011_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/253517","article-title":"Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States","volume":"2012","author":"Patel","year":"2012","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.hoc.2026.05.011_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tgh.2020.01.06","article-title":"Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"6","author":"Bento De Sousa","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.011_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.011_bib16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.011_bib17","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.011_bib18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","article-title":"Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study","volume":"16","author":"Mehta","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib20","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.31318","article-title":"Liver transplantation following Yttrium-90 radioembolization: 15-year experience in 207-Patient cohort","volume":"73","author":"Gabr","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","article-title":"Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation","volume":"234","author":"Lencioni","year":"2005","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib24","first-page":"452","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Orthod"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.011_bib25","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.011_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.liver.2025.100285","article-title":"Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer","volume":"19","author":"Shivega","year":"2025","journal-title":"J Liver Transplantation"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1102\/1470-7330.2012.0044","article-title":"Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring","volume":"12","author":"Hennedige","year":"2013","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in At-Risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamasurg.2016.3310","article-title":"Evaluation of patients with hepatocellular carcinomas that do not produce \u03b1-Fetoprotein","volume":"152","author":"Agopian","year":"2017","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"The model for end-stage liver disease (MELD)","volume":"45","author":"Kamath","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.hoc.2026.05.011_bib32","unstructured":"Organ Procurement and Transplantation Network. Guidance to Liver Transplant Programs and the National Liver Review Board for Adult MELD Exceptions for Transplant Oncology, 2025, OPTN. Available at: https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/optn\/20200804_nlrb_adult_other_guidancepdf.pdf."},{"issue":"6","key":"10.1016\/j.hoc.2026.05.011_bib33","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/hep.31223","article-title":"Effect of mandatory 6-Month waiting period on waitlist and transplant outcomes in patients with hepatocellular carcinoma","volume":"72","author":"Nagai","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib34","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/hep.27704","article-title":"Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States","volume":"61","author":"Heimbach","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/hbsn-21-350","article-title":"Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients","volume":"11","author":"Koh","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.hoc.2026.05.011_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1366607","article-title":"Liver transplantation vs liver resection in HCC: promoting extensive collaborative research through a survival meta-analysis of meta-analyses","volume":"14","author":"Martinino","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/COC.0b013e3181ec63dd","article-title":"Comparative analysis of outcome in patients with hepatocellular carcinoma exceeding the Milan criteria treated with liver transplantation versus partial hepatectomy","volume":"34","author":"Canter","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.011_bib38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/SLA.0000000000001866","article-title":"Liver resection and transplantation for patients with hepatocellular carcinoma beyond Milan criteria","volume":"264","author":"Zaydfudim","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.011_bib39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archsurg.2007.39","article-title":"Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators","volume":"143","author":"Zimmerman","year":"2008","journal-title":"Arch Surg"},{"key":"10.1016\/j.hoc.2026.05.011_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/tgh.2017.09.06","article-title":"Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?","volume":"2","author":"Lerut","year":"2017","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.trre.2015.02.003","article-title":"mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation?","volume":"29","author":"Duvoux","year":"2015","journal-title":"Transplant Rev"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2021.0217","article-title":"The management of post-transplantation recurrence of hepatocellular carcinoma","volume":"28","author":"Rajendran","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.011_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"02","key":"10.1016\/j.hoc.2026.05.011_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-828896","article-title":"Liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"24","author":"Heimbach","year":"2004","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.011_bib48","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1477-2574.2011.00298.x","article-title":"Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination","volume":"13","author":"Heimbach","year":"2011","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4240\/wjgs.v14.i1.1","article-title":"Current status of liver transplantation for cholangiocarcinoma","volume":"14","author":"Twohig","year":"2022","journal-title":"World J Gastrointest Surg"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.011_bib51","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.011_bib52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3390\/cancers16111946","article-title":"Cholangiocarcinoma: the Current status of surgical options including liver transplantation","volume":"16","author":"Esmail","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.011_bib54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib55","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1186\/s12885-024-12970-8","article-title":"Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma","volume":"24","author":"Li","year":"2024","journal-title":"BMC Cancer"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.011_bib56","first-page":"e16218","article-title":"Clinicopathologic and treatment characteristics of mixed hepatocellular carcinoma-intrahepatic cholangiocarcinoma (HCC-ICC)","volume":"42","author":"Ozer","year":"2024","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib57","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.ajt.2024.12.253","article-title":"Living donor liver transplant for intrahepatic cholangiocarcinoma or mixed disease: time for a paradigm shift?","volume":"25","author":"Sethi","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hoc.2026.05.011_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/LVT.0000000000000589","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma","author":"Kodali","year":"2025","journal-title":"Liver Transplant"},{"key":"10.1016\/j.hoc.2026.05.011_bib59","unstructured":"Organ Procurement and Transplantation Network. Guidance to Liver Transplant Programs and the National Liver Review Board for Adult MELD Exceptions for Transplant Oncology. OPTN; 2024. Available at: https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/optn\/liver_nlrb_june-2024_pn.pdf."},{"issue":"12","key":"10.1016\/j.hoc.2026.05.011_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.gassur.2025.102211","article-title":"Liver transplant for intrahepatic cholangiocarcinoma: current evidence and clinical practice recommendations","volume":"29","author":"Anteby","year":"2025","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.011_bib61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","article-title":"Biliary tract cancers, Version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Benson","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jamcollsurg.2019.12.037","article-title":"Living donor liver transplantation for perihilar cholangiocarcinoma: outcomes and complications","volume":"231","author":"Tan","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.011_bib63","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.21107","article-title":"Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma","volume":"13","author":"Mantel","year":"2007","journal-title":"Liver Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.011_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrad025","article-title":"Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: Multicentre, retrospective cohort study","volume":"7","author":"Hoogwater","year":"2023","journal-title":"BJS Open"},{"key":"10.1016\/j.hoc.2026.05.011_bib65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.20517\/2394-5079.2022.75","article-title":"Liver transplantation for perihilar cholangiocarcinoma. Do we need to move forward?","volume":"9","author":"Dopazo","year":"2023","journal-title":"Hepatoma Res"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.011_bib66","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/01.tp.0000253551.43583.d1","article-title":"Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"82","author":"Heimbach","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.011_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jamcollsurg.2012.03.014","article-title":"Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?","volume":"215","author":"Rosen","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.011_bib68","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archsurg.2011.116","article-title":"Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center","volume":"146","author":"Hong","year":"2011","journal-title":"Arch Surg"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/SLA.0000000000002574","article-title":"Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease","volume":"267","author":"Ethun","year":"2018","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.011_bib70","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1097\/TP.0000000000003539","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates","volume":"105","author":"Ziogas","year":"2021","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.011_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.3112","article-title":"Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant","volume":"156","author":"Lai","year":"2021","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.011_bib72","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/jhep.2001.23311","article-title":"Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective","volume":"33","author":"Sarasin","year":"2001","journal-title":"Hepatology"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:30:50Z","timestamp":1784579450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0889858826000511"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver Transplantation for Liver and Perihilar Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}